CVR: 39426005
Secondary names: Danish Cannabinoids Pharmaceuticals A/S, Danish Cannabis Pharmaceuticals A/S
Previous names: DANCANN IVS, DANCANN PHARMA IVS, DANCANN PHARMA ApS
DANCANN PHARMA A/S was a Danish company of the type Aktieselskab based in Ansager, founded in 2018. The company was registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named DANCANN PHARMA ApS and DANCANN PHARMA IVS. The company is owned by JEQ Capital AB. The company has 1 employee. In 2024, the company reported revenue of DKK 0 and a net result of DKK -8,346,000 compared with DKK -62,260,000 the year before. Equity amounted to DKK 14,620,000.
Selskabets formål er fremstilling og udvikling af cannabinoid-baseret medicin samt handel med denne - herunder eksport og import - samt anden virksomhed og aktiviteter, der efter bestyrelsens skøn står i forbindelse hermed.
Ved dekret af 3. juli 2026 har Retten i Esbjerg taget DANCANN PHARMA A/S under konkursbehandling. Kurator: Advokat Corna Levin Munch, Bavnehøjvej 5, 6700 Esbjerg. Sagsnr. SKS 15-169/2026.
Source: Statstidende — updated daily
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringCompared to 129 companies in Fremstilling af farmaceutiske præparater
Comparison is based on industry median values
Screen owners and management against the Danish FSA's official PEP lists
Contact info changed: new phone: 69160393, new email: [email protected], new website: https://dancann.com (July 9, 2026).
On July 9, 2026, DANCANN PHARMA A/S was placed under bankruptcy proceedings.
On July 7, 2026, a notice regarding DANCANN PHARMA A/S was published in Statstidende: Konkursdekret (S03072026-182).
As of July 3, 2026, DELOITTE STATSAUTORISERET REVISIONSPARTNERSELSKAB has stepped down as auditor of DANCANN PHARMA A/S.
As of July 3, 2026, Jes Lunde has left the board of directors of DANCANN PHARMA A/S.
As of July 3, 2026, Christian Carlsen has left the board of directors of DANCANN PHARMA A/S.
As of July 3, 2026, Carsten Trads has left the board of directors of DANCANN PHARMA A/S.
As of July 3, 2026, Jeppe Krog Rasmussen has left the board of directors of DANCANN PHARMA A/S.
As of July 3, 2026, Jeppe Krog Rasmussen has stepped down as adm. dir. of DANCANN PHARMA A/S.
Contact info changed: new phone: 69160393, new email: [email protected], new website: https://dancann.com (April 20, 2026).
As of April 20, 2026, Jeppe Krog Rasmussen is registered as adm. dir. of DANCANN PHARMA A/S.
Contact info changed: new phone: 69160393, new email: [email protected], new website: https://dancann.com (March 24, 2026).
As of March 13, 2026, Peter Hauberg Søndergaard has stepped down as adm. dir. of DANCANN PHARMA A/S.
As of November 1, 2025, Peter Hauberg Søndergaard is registered as adm. dir. of DANCANN PHARMA A/S.
As of November 1, 2025, Jeppe Krog Rasmussen has stepped down as adm. dir. of DANCANN PHARMA A/S.
DANCANN PHARMA A/S has published its annual report for 2024. Revenue came to DKK 0, and the net result was DKK -8,346,000.
As of December 10, 2024, Jes Lunde has joined the board of directors of DANCANN PHARMA A/S.
As of December 10, 2024, is registered as an owner of DANCANN PHARMA A/S with an ownership share of 5%.
DANCANN PHARMA A/S has published its annual report for 2023. Revenue came to DKK 0, and the net result was DKK -62,260,000.
As of October 26, 2023, Louise Bertelsen Forman has left the board of directors of DANCANN PHARMA A/S.
As of October 26, 2023, Alexander Schoeneck has left the board of directors of DANCANN PHARMA A/S.
DANCANN PHARMA A/S has published its annual report for 2022. Revenue came to DKK 0, and the net result was DKK -16,064,000.
As of May 30, 2023, Louise Bertelsen Forman has joined the board of directors of DANCANN PHARMA A/S.
As of May 30, 2023, Tue Østergaard has left the board of directors of DANCANN PHARMA A/S.
As of September 20, 2022, Jeppe Krog Rasmussen has joined the board of directors of DANCANN PHARMA A/S.
As of September 20, 2022, Alexander Schoeneck has joined the board of directors of DANCANN PHARMA A/S.
As of September 20, 2022, Magnus Østergaard Dahlmann has left the board of directors of DANCANN PHARMA A/S.
As of September 20, 2022, Per Wester has left the board of directors of DANCANN PHARMA A/S.
DANCANN PHARMA A/S has published its annual report for 2021. Revenue came to DKK 0, and the net result was DKK -11,750,000.
As of April 27, 2022, Christian Carlsen has joined the board of directors of DANCANN PHARMA A/S.
As of April 27, 2022, Tue Østergaard has joined the board of directors of DANCANN PHARMA A/S.
As of April 27, 2022, Jeppe Krog Rasmussen has left the board of directors of DANCANN PHARMA A/S.
As of April 26, 2022, Christian Carlsen has left the board of directors of DANCANN PHARMA A/S.
DANCANN PHARMA A/S has published its annual report for 2020. Gross profit came to DKK -4,829,650, and the net result was DKK -4,254,612.
As of April 28, 2021, DELOITTE STATSAUTORISERET REVISIONSPARTNERSELSKAB has been appointed auditor of DANCANN PHARMA A/S.
As of April 28, 2021, A/S PSE 17 NR. 1056 has stepped down as auditor of DANCANN PHARMA A/S.
As of April 28, 2021, Christian Carlsen has joined the board of directors of DANCANN PHARMA A/S.
As of March 19, 2021, Carsten Trads has joined the board of directors of DANCANN PHARMA A/S.
As of March 19, 2021, Magnus Østergaard Dahlmann has joined the board of directors of DANCANN PHARMA A/S.
As of March 18, 2021, Carsten Trads has left the board of directors of DANCANN PHARMA A/S.
As of March 18, 2021, Magnus Østergaard Dahlmann has left the board of directors of DANCANN PHARMA A/S.
As of July 6, 2020, Jeppe Krog Rasmussen has joined the board of directors of DANCANN PHARMA A/S.
On July 6, 2020, the company changed its name from DANCANN PHARMA ApS to DANCANN PHARMA A/S.
On June 26, 2020, the company changed its name from DANCANN PHARMA IVS to DANCANN PHARMA ApS.
As of April 8, 2020, A/S PSE 17 NR. 1056 has been appointed auditor of DANCANN PHARMA A/S.
As of April 8, 2020, Carsten Trads has joined the board of directors of DANCANN PHARMA A/S.
As of April 8, 2020, Magnus Østergaard Dahlmann has joined the board of directors of DANCANN PHARMA A/S.
As of April 8, 2020, Per Wester has joined the board of directors of DANCANN PHARMA A/S.
DANCANN PHARMA A/S has published its annual report for 2019. Gross profit came to DKK -421,797, and the net result was DKK -1,239,612.
On December 4, 2019, the company changed its name from DANCANN IVS to DANCANN PHARMA IVS.
DANCANN PHARMA A/S has published its interim report for the period March 20, 2018 – December 31, 2018.
As of March 20, 2018, Jeppe Krog Rasmussen is registered as adm. dir. of DANCANN PHARMA A/S.
DANCANN PHARMA A/S was founded on March 20, 2018.
companydata.dk